TWST Twist Bioscience Corporation - Common Stock

Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 from $1,273 while maintaining a Buy rating on the pharma stock. But perhaps the more important change was in Foundayo estimates. Guggenheim sharply raised its revenue forecasts for Lilly’s oral obesity drug, […]

A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.

Key TakeawaysAnthropic Ripple: Twist Bioscience stock jumped 16% on Thursday, September 24, after Leerink Partners called the company the single most important beneficiary of Anthropic’s expanding biology research. Split Street: TIKR tracks 13 analysts: 7 buys, 2 outperforms, 3 holds, 1 sell.

Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company (NYSE:LLY). As part of the strategic partnership, Twist will provide antibody characterization data […]

Twist Bioscience (TWST) has surged 493% over 52 weeks, maintaining strong technical momentum. Shares just hit a new all-time high and has a 100% “Buy” technical opinion. However, its RSI of 72.95 and high short interest signal potential overextension. Consensus price targets are well below current levels, suggesting limited upside....

It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.

Twist traded as high as $163.70 on Thursday and finished the session about 9% higher near $156.

Haemonetics and Twist Bioscience stocks surged to more than five-year highs on Thursday, as fresh growth opportunities drew cheer from Wall Street.

On 16 September 2026, Twist Bioscience announced an agreement with Lilly TuneLab, under which Twist will provide antibody characterization data services using preferred Twist protocols to generate high-quality wet lab data that feed Lilly’s AI/ML drug discovery models. This collaboration effectively plugs Twist’s DNA and antibody capabilities into Lilly’s AI-driven discovery ecosystem, potentially deepening Twist’s role in data-rich, AI-enhanced antibody development workflows across the...

Healthcare stocks were slightly lower late Wednesday afternoon, with the NYSE Healthcare Index fract

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]

Healthcare stocks were edging higher pre-bell Wednesday, with the State Street Health Care Select Se

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

Nvidia was ARK’s biggest August purchase, with roughly 548,000 shares added during the month.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 3.1% a

Claude-designed proteins successfully bound to 14 of 15 targets in independent testing by Adaptyv Bio and Twist Bioscience.

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.

AI-enabled drug discovery orders drive triple-digit growth as guidance rises.

In early August 2026, Twist Bioscience completed a US$300 million follow-on common stock offering at US$96 per share after raising its fiscal 2026 revenue guidance to US$456 million–US$457 million and reporting third-quarter sales of US$118.38 million despite a net loss of US$35.05 million. Alongside this capital raise and upgraded outlook, Twist is addressing legacy securities litigation through a proposed US$17.05 million class-action settlement process that could help clear a legal...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

Moby summary of Twist Bioscience Corporation's Q3 2026 earnings call

Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports.

Twist Bioscience Corp (TWST) reports 23% revenue growth and raises fiscal 2026 guidance, driven by surging AI-enabled drug discovery demand.

Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth. The company raised its full-year revenue outlook and said it remains on track to reach adjusted EBITDA breakeven in the fiscal four

Twist Bioscience (NASDAQ:TWST) shares fell 4. 2% in pre-market trading after the synthetic biology company reported fiscal third-quarter results that exceeded revenue expectations but fell short of Wall Street’s earnings forecast.

Twist Bioscience (TWST) delivered earnings and revenue surprises of -12.00% and +3.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of 0.00% and +7.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alpha Cognition Inc. (ACOG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Twist Bioscience stock has delivered very strong long term gains over the last three years, yet the current valuation screens as expensive on several checks, which raises the question of how much optimism is already in the price. Twist Bioscience has returned 261.2% over the past three years, which puts extra focus on whether the recent share price level is still supported by fundamentals. The long term investment case can be supported by expectations for revenue growth from its synthetic...

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The fund reported strong absolute returns and modestly outperformed the Russell 2000® Growth Index, which gained 25.7%. Global equities rebounded as resilient US growth, moderating inflation, strong earnings and […]

Cathie Wood Trims AMD to Fund Bigger SpaceX Bet

Wood's ETFs sell stocks that have had strong runs to pay for other positions.

ARK's purchases come as investors closely watch progress on U.S. crypto legislation, including the CLARITY Act and stablecoin regulation efforts.

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Cathie Wood Unveils Major Portfolio Reset With SpaceX, Meta Buys and AMD Cuts